MackayLKRahimpourAMaJZ, et al. The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat Immunol. 2013;14:1294-1301.
2.
MuellerSNZaidACarboneFR. Tissue-resident T cells: Dynamic players in skin immunity. Front Immunol. 2014;5:332.
3.
ClarkRA. Resident memory T cells in human health and disease. Sci Transl Med. 2015;7(269):269rv1.
4.
TakamuraS. Niches for the long-term maintenance of tissue-resident memory T cells. Front Immunol. 2018;9:1214.
5.
HiraiTWhitleySKKaplanDH. Migration and function of memory CD8+ T cells in skin. J Invest Dermatol. 2020;140:748-755.
6.
CheukSWikenMBlomqvistL, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192:3111-3120.
7.
MatosTRO’MalleyJTLowryEL, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing αβ T cell clones. J Clin Invest. 2017;127:4031-4041.
8.
WuHLiaoWLiQ, et al. Pathogenic role of tissue-resident memory T cells in autoimmune diseases. Autoimmun Rev. 2018;17:906-911.
9.
KuriharaKFujiyamaTPhadungsaksawasdiPItoTTokuraY. Significance of IL-17A-producing CD8+CD103+ skin resident memory T cells in psoriasis lesion and their possible relationship to clinical course. J Dermatol Sci. 2019;95:21-27.
10.
SgambelluriFDianiMAltomareA, et al. A role for CCR5(+)CD4 T cells in cutaneous psoriasis and for CD103(+) CCR4(+) CD8 Teff cells in the associated systemic inflammation. J Autoimmun. 2016;70:80-90.
11.
VoSWatanabeRKoguchi-YoshiokaH, et al. CD8 resident memory T cells with interleukin 17A-producing potential are accumulated in disease-naïve nonlesional sites of psoriasis possibly in correlation with disease duration. Br J Dermatol. 2019;181:410-412.
12.
CorgnacSBoutetMKfouryMNaltetCMami-ChouaibF. The emerging role of CD8+ tissue resident memory T (TRM) cells in antitumor immunity: A unique functional contribution of the CD103 integrin. Front Immunol. 2018;9:1904.
13.
MackayLKBraunAMacleodBL, et al. Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention. J Immunol. 2015;194:2059-2063.
14.
KuriharaKFujiyamaTPhadungsaksawasdiPItoTHondaTTokuraY. Epidermal CD8+CD103+ skin resident memory T cells in psoriasis plaques are reduced in number but remain in the basement membrane zone after topical application of corticosteroid and vitamin D3. J Dermatol Sci. 2022;105(3):192-194.
15.
StroberBStein GoldLBissonnetteR, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;S0190-9622(22):02219.
16.
MooneyNTeagueJGehadAMcHaleKRubensteinDClarkR. Tapinarof inhibits the formation, cytokine production, and persistence of resident memory T cell in vitro. J Invest Dermatol. 2022;142(8):B26.
17.
Gallais SerezalIClassonCCheukS, et al. Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome. J Invest Dermatol. 2018;138:1754-1763.
18.
ChenLShenZ. Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders. Cell Mol Immunol. 2020;17:64-75.
19.
KatzELHarrisJE. Translational research in vitiligo. Front Immunol. 2021;12:624517.
20.
HawkesJEKruegerJGYanBYChanTC, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201:1605-1613.
21.
MehtaHMashikoSAngsanaJ, et al. Differential changes in inflammatory mononuclear phagocyte and T cell profiles within psoriatic skin during treatment with guselkumab versus secukinumab. J Invest Dermatol. 2021;141:1707-1718.
22.
GordonKBArmstrongAWFoleyP, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019;139(12):2437-2446.
23.
BlauveltALeonardiCLGooderhamM, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: A phase 3 randomized clinical trial. JAMA Dermatol. 2020;156:649-658.
24.
GordonKBStroberBLebwohlM, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392:650-661.
25.
KruegerJGFerrisLKMenterA, et al. Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116-124.
